ORMP Unusual Options Activity — 2026-01-14

📅 January 14, 2026 | 🔥 Unusual Activity Detected

---

🎯 The Quick Take

Someone just sold $2.3 MILLION worth of short-term puts on Oramed Pharmaceuticals (ORMP), a clinical-stage pharma company developing the world's first oral insulin. With 13,000 contracts exchanged at the $5 strike expiring in just 2 days (January 16), this trader is collecting premium while betting the stock stays above $5 through the ex-dividend date. The timing is notable - January 16 is both the option expiration AND the ex-dividend date for a $0.25/share payout.

---

🏢 Company Overview

Oramed Pharmaceuticals Inc is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. Their flagship candidate ORMD-0801 aims to be the first FDA-approved oral insulin for Type 2 diabetes.

• 💊 Sector: Pharmaceutical Preparations
• 💰 Market Cap: ~$135M
• 📈 Current Price: $3.62
• 📊 52-Week Range: $1.82 - $3.54

---

💰 The Option Flow Breakdown

📊 What Just Happened

• 🐋 Massive Size: 13,000 put contracts sold to open
• 💵 Premium Collected: $2.3 million in upfront income
• ⏰ Ultra-Short Dated: Only 2 days until expiration
• 📍 Strike Price: $5.00 (38% above current stock price of $3.55)

🤓 What This Actually Means

Translation for us regular folks: A trader just collected $2.3 million by agreeing to buy 1.3 million shares of ORMP at $5 if the stock somehow rockets above that level in the next 2 days. Given the stock is trading at $3.62, this is essentially free money for the put seller unless something extraordinary happens.

Why sell puts at a strike ABOVE the stock price?

• The $5 puts are deep in-the-money, meaning they carry significant intrinsic value
• The seller believes ORMP won't surge 38%+ in 2 days
• They're comfortable potentially owning 1.3M shares at an effective cost basis around $3.23 (strike minus premium received per share)
• The timing with the ex-dividend date suggests they want exposure to collect the $0.25 dividend

---

📈 Technical Setup & Chart Check-Up

📊 YTD Chart Analysis

ORMP has been on quite a journey in early 2026. The stock popped 6.42% on January 9 following the Scilex payment news and dividend announcement. It's now trading near the upper end of its 52-week range ($1.82 - $3.54), with recent momentum driven by:

• ✅ $18M Scilex payment received (January 7)
• ✅ $0.25 dividend declared (ex-date January 16)
• ✅ Lifeward strategic partnership announced (January 13)

---

🎯 Gamma-Based Support & Resistance Analysis

Current GEX Positioning:

• 📊 Total Call Gamma: 0.10 (Bullish bias)
• 📊 Total Put Gamma: 0.004 (Minimal put hedging)
• 🟢 Net GEX Bias: Bullish

The gamma exposure data shows minimal defined support and resistance levels, which is typical for a small-cap biotech with limited options activity. The bullish net GEX bias suggests market makers are positioned for upside rather than downside.

---

📏 Implied Move Analysis

Weekly Expiration (January 16, 2026):

Real talk: That 640% implied volatility is astronomical - even for a biotech. The market is pricing in a massive move, but the negative IV skew (calls more expensive than puts) tells us traders are positioned more for upside than downside.

Expected Range by January 16:

• 🎯 Bull Case (68% probability): Up to $4.96
• 🎯 Base Case: $3.62 (current level)
• 🎯 Bear Case (68% probability): Down to $2.28

---

🎪 Catalysts

📅 Upcoming Events

✅ Recent Catalysts (Already Happened)

• 🎉 January 13, 2026: Lifeward strategic partnership announced - Up to $47M investment, 49.9% ownership stake
• 💰 January 7, 2026: Received $18M from Scilex, bringing total returns to $118M
• 📢 January 7, 2026: Board approved $0.25/share dividend
• 📊 November 17, 2025: Q3 2025 results - $65M net income (9 months), beat estimates by $1.17

---

🎲 Price Targets & Probabilities

Based on gamma levels, implied move ranges, and catalyst proximity:

🐂 Bull Case: $4.50 - $4.96 (25% probability)

• Lifeward deal closes early with favorable terms
• Dividend yield attracts income-focused buyers
• 60-patient trial shows promising early signals
• Alpha Tau holdings appreciate further

⚖️ Base Case: $3.20 - $3.80 (55% probability)

• Stock consolidates around current levels post-dividend
• Market digests Lifeward partnership details
• Normal biotech volatility continues
• Quarterly payments from Scilex provide floor

🐻 Bear Case: $2.28 - $2.80 (20% probability)

• Broader biotech sector weakness
• Investment portfolio (Alpha Tau) declines
• Clinical trial concerns resurface
• Lifeward deal faces shareholder pushback

---

💡 Trading Ideas

🛡️ Conservative: "Dividend Capture + Cash Secured Put"

The Play: Buy shares before January 16 ex-date, collect the dividend, then sell a covered call

• 📍 Entry: Buy 100 shares at ~$3.62 ($362 total)
• 💵 Dividend Income: $25 per 100 shares (January 26 payment)
• 📝 Sell: February $4 call for ~$0.30 ($30 premium)
• 💰 Total Income: $55 on $362 investment = 15.2% return potential
• 🎯 Max Profit: If called away at $4 = $93 profit (25.7%)

Why This Works: You're getting paid to wait with a 7% dividend yield (annualized) plus call premium, with a company that has $52M cash and positive investment returns.

View ORMP February $4 Call

---

⚖️ Balanced: "Post-Dividend Put Spread"

The Play: After ex-dividend date, sell a put spread to collect premium on any weakness

• 📍 Sell: February $3.50 Put
• 📍 Buy: February $2.50 Put (for protection)
• 💵 Net Credit: ~$0.40-0.50 per spread
• 🎯 Max Profit: Keep full premium if ORMP stays above $3.50
• ⚠️ Max Loss: $0.50-0.60 per spread (strike difference minus credit)
• 📊 Break-even: ~$3.00-3.10

Why This Works: Post-dividend sellers often create temporary weakness. This spread profits from the stock staying above $3.50, which is below current prices and above the strong support from investment portfolio value.

View ORMP February $3.50 Put

---

🚀 Aggressive: "Trial Data Anticipation Call"

The Play: Buy longer-dated calls betting on positive 60-patient trial momentum in mid-2026

• 📍 Buy: June $4 Call
• 💵 Cost: ~$0.60-0.80 per contract ($60-80 per contract)
• 🎯 Target: Stock at $5+ by June = 150%+ gain on calls
• ⚠️ Risk: Full premium lost if stock below $4.60 at expiration
• 📊 Break-even: $4.60-4.80

Why This Works: The 60-patient U.S. oral insulin trial data is expected mid-2026. If early signals are positive, this small-cap biotech could see significant moves. You're risking defined premium for asymmetric upside.

View ORMP June $4 Call

---

⚠️ Risk Factors

🔬 Clinical Risk

• ❌ Phase 3 oral insulin trial failed in January 2023, sending stock down 70%
• ❌ 60-patient study may not generate sufficient statistical power
• ❌ FDA pathway for oral insulin remains uncertain

💼 Business Risks

• ❌ HTIT joint venture termination shows partnership execution challenges
• ❌ Lifeward deal requires shareholder approval (not guaranteed)
• ❌ Heavy insider ownership (51.57%) limits liquidity

📉 Market Risks

• ❌ Small-cap biotech volatility (Beta: 1.34)
• ❌ Investment portfolio (Alpha Tau, Scilex) subject to market swings
• ❌ Limited analyst coverage increases information asymmetry

🏥 Competitive Risks

• ❌ GLP-1 drugs (Ozempic, Wegovy) dominating diabetes landscape
• ❌ Injectable insulin improvements reduce oral advantage appeal

---

🎯 The Bottom Line

Real talk: That $2.3M put sale is a high-conviction bet that ORMP won't crash before the ex-dividend date. The trader is essentially saying "I'll take $2.3M in premium and happily own 1.3M shares at an effective price around $3.23 if needed."

Here's how to think about it:

📗 If You're Bullish: The dividend, Lifeward partnership, and positive cash flow from investments create a floor. Consider the conservative dividend capture strategy for steady income, or go aggressive with June calls if you believe in the 60-patient trial.

📒 If You're Watching: Wait for post-dividend weakness to enter. The ex-date often creates selling pressure from dividend-capture traders exiting. The balanced put spread strategy profits from this exact scenario.

📕 If You're Bearish: Stay away. The $2.3M put sale suggests smart money sees downside as limited, and the company's $52M cash + investment returns provide a value floor. Short positions here are fighting the tape.

Mark Your Calendar:

• 📅 January 16: Ex-dividend date (must own before this to get dividend)
• 📅 January 26: Dividend payment ($0.25/share)
• 📅 March 26: Q4 earnings - watch investment portfolio valuations

The lesson here: When someone bets $2.3M that a biotech won't collapse in 2 days, AND there's a dividend catalyst, AND recent positive news - the path of least resistance is probably sideways to up. Don't fight the whale. 🐋

---

⚠️ Disclaimer: This analysis is for educational purposes only and does not constitute financial advice. Options trading involves significant risk of loss. The unusual options activity highlighted represents one trader's view and should not be interpreted as a guaranteed outcome. Always conduct your own due diligence and consider your risk tolerance before trading. Past performance does not guarantee future results.

---

Analysis Date: January 14, 2026 | Data Sources: ThetaData Options Flow, Polygon Stock Data